Do Inhaled Steroids Help Every COPD Patient? What Blood Eosinophils Predict

No, inhaled corticosteroids do not help every person with chronic obstructive pulmonary disease (COPD). A routine blood test, the eosinophil count, helps sort the people likely to gain from a steroid inhaler from those who would mostly absorb its risks. Across the trial evidence the pattern is consistent: the reduction in flare-ups from adding an inhaled steroid grows as the eosinophil count rises and fades toward negligible when the count is very low. Current global guidance treats about 100 and 300 eosinophils per microliter of blood as practical dividing lines, always read together with how often a person actually flares.

Key points#

• Inhaled steroids reduce COPD flare-ups mainly in people with higher blood eosinophil counts and a history of repeated flares.
• Roughly below 100 cells per microliter, benefit is unlikely; at or above 300, the case is strongest; in between the probability rises.
• The count does not predict who will flare in the first place. Past flares do that better.
• Inhaled steroids raise pneumonia risk, and low-eosinophil patients carry that risk while they benefit the least.
• A single count varies over time, so it guides rather than dictates the decision.

Two ledgers, not one#

Every prescribing decision in COPD balances two ledgers. On one side sits the potential benefit: fewer of the exacerbations that land people in urgent care and erode lung function over time. On the other sits harm, chiefly a raised risk of pneumonia. For a long stretch, inhaled steroids were prescribed widely across COPD, an idea borrowed from asthma, where they are foundational treatment. The problem is that COPD is a different disease, and treating it as if everyone belonged in the same box meant many people carried the harm ledger without much on the benefit side.

The eosinophil count turned out to be a useful way to weigh those two ledgers for an individual. Eosinophils are a type of white blood cell tied to the sort of airway inflammation that steroids are good at calming. When there are more of them circulating, a steroid inhaler has more to act on. When there are very few, the inflammation driving the disease is more likely bacterial and neutrophilic, the kind steroids do little for.

How a blood test became a treatment signal#

The signal first emerged not from a brand-new experiment but from re-reading old trial data. A 2015 secondary analysis of two matched trials of fluticasone furoate plus a bronchodilator, published by Pascoe and colleagues in the Lancet Respiratory Medicine, split patients by their eosinophil level. In those at or above 2 percent of white cells, adding the steroid cut moderate and severe flare-ups by roughly 29 percent. In those below that line, the reduction was about 10 percent and not statistically significant. That was an early, widely cited hint that a cheap blood test might flag responders.

Other datasets then converted the percentage into absolute counts and tested the idea from different angles. In the WISDOM withdrawal trial, the patients who worsened after their inhaled steroid was removed tended to cluster at counts of 300 cells per microliter or higher, and the later SUNSET study pointed the same way. One caveat about the strength of this evidence deserves emphasis: most of these eosinophil findings come from secondary or post-hoc analyses of trials built to answer other questions. That is a solid reason to treat the thresholds as pragmatic guideposts rather than sharp biological switches.

What the GOLD numbers actually say#

The 2025 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) folds all of this into a gradient rather than a single cutoff. A count below 100 cells per microliter argues against starting an inhaled steroid, because benefit is unlikely. A count at or above 300 gives the strongest support. The range in between marks a rising, intermediate probability of benefit. A later analysis of the large IMPACT trial, also from Pascoe and colleagues, gave the gradient its clearest shape, showing that the flare-up benefit of steroid-containing regimens climbed steadily with the eosinophil count, from minimal below about 100 cells to substantial above 300.

Two conditions keep this honest. First, GOLD applies the eosinophil logic only to people who keep having flare-ups despite bronchodilator treatment. The count modifies the decision; it does not, on its own, create a reason to prescribe. Second, the count is a weak predictor of who will flare at all. A pooled analysis of 22,125 patients across 11 trials, published by Singh and colleagues in Respiratory Research in 2020, found that a baseline eosinophil count predicts future flare-ups poorly, whereas a person's own history of flares predicts them far better. So the count answers a narrow question, whether a steroid is likely to help this particular person, and not the broader one of who is prone to flaring.

The pneumonia side of the balance#

None of this would matter if inhaled steroids were free of downside, but they are not. In COPD they raise the risk of pneumonia, an effect seen repeatedly and most strongly with fluticasone-based products. A leading explanation is that inhaled steroids blunt local airway defenses, including antimicrobial peptides such as cathelicidin, and can shift the airway community toward bacterial dominance. People with low eosinophil counts already lean toward that bacterial, neutrophilic pattern, and they are precisely the group that gains the least from the drug.

Line the ledgers up and the reasoning behind the thresholds becomes clear. The extra pneumonia risk is not confined to the people who benefit. Patient-level analyses have found that those with low eosinophil counts, who gain the least, carry at least as much of the added pneumonia burden. A person with very low eosinophils is therefore being asked to accept a real infection risk for little expected reward. The specific drug matters as well, with pooled data linking fluticasone to a higher pneumonia signal than budesonide. GOLD also flags repeated pneumonia and certain mycobacterial infections as separate reasons to steer away from inhaled steroids, whatever the eosinophil number happens to be.

Reading the number with humility#

A single eosinophil count is a snapshot of something that moves. Values drift with the time of day, with infections, with courses of oral steroids, and with the season, so a person can sit on one side of a threshold one week and the other side the next. That is why guidance leans on repeated measurements where possible, and why a borderline value should not overturn a strong clinical story in either direction. The eosinophil count is best thought of as a dial that makes an already flare-prone patient's decision more rational, not a verdict that settles it.